LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Stock List・Innoviva Inc
Search

Innoviva Inc

Closed

SectorHealthcare

22.93 2.23

Buy

Price update 10 Jun 2026, 19:59 UTC

BuySell

Overview

Share price change

24h

Current

Min

22.5

Max

23.32

Key metrics

By Trading Economics

Income

-55M

187M

Sales

-20M

98M

P/E

Sector Avg

3.596

49.052

EPS

0.47

Profit margin

190.415

Employees

159

EBITDA

-160M

48M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+53.06% upside

Dividends

By Dow Jones

Next Earnings

4 Aug 2026

Market Stats

By TradingEconomics

Market Cap

-54M

1.6B

Previous open

20.7

Previous close

22.93

News Sentiment

By Acuity

50%

50%

154 / 344 Healthcare

Innoviva Inc Chart

Past performance is not a reliable indicator of future results.

Related News

10 Jun 2026, 23:36 UTC

Earnings

Correction to Oracle Reports Higher 4Q Profit Article

DJ

Read

10 Jun 2026, 23:19 UTC

Hot Stocks

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

DJ

Read

10 Jun 2026, 23:09 UTC

Major Market Movers

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

DJ

Read

10 Jun 2026, 23:04 UTC

Earnings

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

DJ

Read

10 Jun 2026, 20:44 UTC

Major Market Movers

Caterpillar Raises Quarterly Dividend 8%

DJ

Read

10 Jun 2026, 23:49 UTC

Acquisitions, Mergers, Takeovers

Elliott: Northern Star Should Take No Options Off The Table

DJ

Read

10 Jun 2026, 23:48 UTC

Acquisitions, Mergers, Takeovers

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

DJ

Read

10 Jun 2026, 23:48 UTC

Acquisitions, Mergers, Takeovers

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

DJ

Read

10 Jun 2026, 23:47 UTC

Market Talk

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

DJ

Read

10 Jun 2026, 23:47 UTC

Acquisitions, Mergers, Takeovers

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

DJ

Read

10 Jun 2026, 23:46 UTC

Acquisitions, Mergers, Takeovers

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

DJ

Read

10 Jun 2026, 23:38 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Read

10 Jun 2026, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

DJ

Read

10 Jun 2026, 23:38 UTC

Market Talk

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

DJ

Read

10 Jun 2026, 23:32 UTC

Market Talk

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

DJ

Read

10 Jun 2026, 23:20 UTC

Market Talk

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

DJ

Read

10 Jun 2026, 22:05 UTC

Market Talk

Correction to Bank of Canada Stays on Hold Market Talk

DJ

Read

10 Jun 2026, 21:57 UTC

Earnings

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Read

10 Jun 2026, 21:52 UTC

Earnings

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Read

10 Jun 2026, 21:35 UTC

Earnings

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Read

10 Jun 2026, 21:22 UTC

Earnings

Oracle Stock Slides on Increased Capital Spending -- WSJ

DJ

Read

10 Jun 2026, 20:50 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

DJ

Read

10 Jun 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

DJ

Read

10 Jun 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

DJ

Read

10 Jun 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

DJ

Read

10 Jun 2026, 20:39 UTC

Market Talk
Earnings

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

DJ

Read

10 Jun 2026, 20:34 UTC

Earnings

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Read

10 Jun 2026, 20:33 UTC

Earnings

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

DJ

Read

10 Jun 2026, 20:33 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

DJ

Read

10 Jun 2026, 20:33 UTC

Market Talk
Earnings

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

DJ

Read

Peer Comparison

Price change

Innoviva Inc Forecast

Price Target

By TipRanks

53.06% upside

12 Months Forecast

Average 34.5 USD  53.06%

High 46 USD

Low 18 USD

Based on 4 Wall Street analysts offering 12 month price targets forInnoviva Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

4 ratings

3

Buy

0

Hold

1

Sell

Based on 4 analysts giving stock ratings to Innoviva Inc - Dist in the past 3 months.

Sentiment

By Acuity

154 / 344 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Other stocks from the sector

LLY

Eli Lilly and Co.

1,136.41

↓-0.5%

JNJ

Johnson and Johnson

238.85

↑ +0.91%

ABBV

AbbVie Inc

225.29

↑ +0.05%

UNH

UnitedHealth Group Inc

407.06

↓-1.28%

MRK

Merck & Co Inc.

119

↓-0.38%
help-icon Live chat